Montanaro Asset Management Ltd Has $30.84 Million Position in Bruker Co. (NASDAQ:BRKR)

Montanaro Asset Management Ltd lifted its holdings in Bruker Co. (NASDAQ:BRKR) by 10.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 446,500 shares of the medical research company’s stock after buying an additional 43,200 shares during the period. Bruker comprises 5.5% of Montanaro Asset Management Ltd’s holdings, making the stock its 2nd largest holding. Montanaro Asset Management Ltd owned approximately 0.29% of Bruker worth $30,835,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. TD Asset Management Inc boosted its stake in Bruker by 7.4% during the first quarter. TD Asset Management Inc now owns 1,788,763 shares of the medical research company’s stock worth $168,036,000 after buying an additional 123,984 shares during the period. Atria Investments Inc purchased a new position in shares of Bruker during the 1st quarter worth about $1,142,000. Point72 Asset Management L.P. bought a new position in Bruker during the 2nd quarter valued at about $36,472,000. Epoch Investment Partners Inc. raised its position in Bruker by 15.2% in the 1st quarter. Epoch Investment Partners Inc. now owns 466,865 shares of the medical research company’s stock worth $43,857,000 after purchasing an additional 61,429 shares during the period. Finally, Assenagon Asset Management S.A. lifted its stake in Bruker by 1,694.4% in the second quarter. Assenagon Asset Management S.A. now owns 202,733 shares of the medical research company’s stock worth $12,936,000 after purchasing an additional 191,435 shares during the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BRKR has been the topic of several recent analyst reports. TD Cowen reduced their price target on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a report on Wednesday. Citigroup reduced their target price on Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday. Barclays lowered their target price on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research note on Wednesday. Wolfe Research downgraded shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Finally, Wells Fargo & Company lowered their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Bruker presently has an average rating of “Moderate Buy” and a consensus target price of $79.36.

Bruker Stock Performance

BRKR stock opened at $57.73 on Friday. Bruker Co. has a one year low of $54.55 and a one year high of $94.86. The firm has a market cap of $8.74 billion, a price-to-earnings ratio of 27.75, a PEG ratio of 2.83 and a beta of 1.20. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.75 and a current ratio of 1.66. The firm has a 50-day simple moving average of $63.64 and a two-hundred day simple moving average of $66.21.

Bruker (NASDAQ:BRKR) last announced its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The firm had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. During the same quarter last year, the business earned $0.74 earnings per share. Bruker’s revenue was up 16.4% on a year-over-year basis. On average, equities analysts forecast that Bruker Co. will post 2.39 EPS for the current fiscal year.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.